Point72 Asia Singapore Pte. Ltd. Has $61,000 Stock Holdings in OPKO Health, Inc. (NASDAQ:OPK)

Point72 Asia Singapore Pte. Ltd. trimmed its stake in shares of OPKO Health, Inc. (NASDAQ:OPK) by 55.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 41,589 shares of the biotechnology company’s stock after selling 51,110 shares during the quarter. Point72 Asia Singapore Pte. Ltd.’s holdings in OPKO Health were worth $61,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. ProShare Advisors LLC lifted its holdings in shares of OPKO Health by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 91,730 shares of the biotechnology company’s stock worth $135,000 after acquiring an additional 30,182 shares during the period. Nuveen Asset Management LLC raised its position in OPKO Health by 42.3% during the fourth quarter. Nuveen Asset Management LLC now owns 1,432,404 shares of the biotechnology company’s stock valued at $2,106,000 after purchasing an additional 425,484 shares in the last quarter. Numerai GP LLC bought a new stake in OPKO Health during the fourth quarter worth $205,000. Millennium Management LLC lifted its stake in OPKO Health by 85.3% during the fourth quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company’s stock worth $6,745,000 after purchasing an additional 2,112,382 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of OPKO Health by 4.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 186,783 shares of the biotechnology company’s stock valued at $275,000 after purchasing an additional 8,064 shares in the last quarter. 64.63% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. StockNews.com cut OPKO Health from a “hold” rating to a “sell” rating in a report on Monday, May 5th. JPMorgan Chase & Co. began coverage on OPKO Health in a research report on Friday, April 25th. They issued a “neutral” rating on the stock. Barrington Research reissued an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a research note on Thursday, May 1st. Finally, HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research note on Monday, April 7th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, OPKO Health presently has an average rating of “Hold” and a consensus price target of $2.75.

OPKO Health Price Performance

Shares of OPK opened at $1.33 on Monday. OPKO Health, Inc. has a 52 week low of $1.19 and a 52 week high of $2.04. The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of -7.00 and a beta of 1.42. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The stock has a fifty day moving average of $1.51 and a 200-day moving average of $1.56.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.03). The firm had revenue of $149.90 million during the quarter, compared to analyst estimates of $163.13 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. OPKO Health’s revenue for the quarter was down 13.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.12) EPS. As a group, sell-side analysts anticipate that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Insider Transactions at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 200,000 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were bought at an average price of $1.74 per share, for a total transaction of $348,000.00. Following the completion of the acquisition, the chief executive officer now owns 213,501,448 shares in the company, valued at approximately $371,492,519.52. This trade represents a 0.09% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders have bought 767,434 shares of company stock worth $1,238,312. Insiders own 49.69% of the company’s stock.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.